A landmark study involving nearly 100,000 Americans has unveiled thousands of previously unknown genetic variants that fundamentally alter how individuals respond to common prescription medications. Published Wednesday in the journal Science Translational Medicine, the findings represent a significant leap forward in the field of pharmacogenomics—the study of how genes influence drug response—by correcting a long-standing bias toward populations of European ancestry in genomic research.
The study, which utilized data from the National Institutes of Health’s (NIH) ambitious All of Us Research Program, discovered that every single participant possessed at least one clinically relevant variant in 16 key pharmacogenes. Furthermore, the analysis determined that one in four participants had previously been prescribed a medication whose efficacy or safety profile could be directly influenced by these specific genetic markers.
Correcting the Genomic Ancestry Gap
Historically, precision medicine has been hampered by a lack of diversity in genomic databases. Major repositories, such as the U.K. Biobank, have been heavily skewed toward individuals of European descent. This imbalance has meant that diagnostic tools and therapeutic guidelines derived from these datasets often underperform or fail entirely when applied to Black, Hispanic, Asian, and other minority populations.
The All of Us Research Program was specifically designed to bridge this divide, with a mandate to recruit one million Americans from diverse backgrounds. By leveraging this diverse cohort, researchers were able to identify genetic variants that were largely invisible in previous studies. This inclusivity is not merely a matter of equity; it is a clinical imperative. If a genetic test is used to guide treatment, its accuracy depends on the data used to calibrate it. When that data is limited, the risk of misdiagnosis or improper dosing increases significantly for marginalized groups.
Loren Saulsberry, a health policy researcher who studies equity in pharmacogenomics and was not involved in the study, noted the significance of the findings. "This really furthers the emerging evidence of how genetically guided clinical care adds benefit across a diverse population," Saulsberry said. "Having such a diverse dataset to start with will help limit disparities in outcomes as the findings are translated into clinical use."
The Mechanism of Pharmacogenes
Pharmacogenes are specific genes that encode proteins—often enzymes—involved in the absorption, metabolism, and elimination of drugs. Variations in these genes can dictate the therapeutic outcome of a treatment. For instance, some variants may cause a person to metabolize a drug too quickly, rendering it ineffective, while others might cause a patient to process a drug too slowly, leading to toxic levels of the medication accumulating in the bloodstream.
The study focused on 16 high-impact genes that govern the metabolism of widely used medications, including:
- Selective Serotonin Reuptake Inhibitors (SSRIs): Common antidepressants where genetic variants can predict side effects or lack of response.
- Statins: Cholesterol-lowering drugs where genetics may influence the risk of muscle-related side effects.
- Chemotherapy Agents: Where precise dosing is essential to balance efficacy against severe toxicity.
- Plavix (clopidogrel): A common blood thinner where genetic variants can mean the difference between preventing a heart attack or stroke and suffering a life-threatening event due to drug failure.
Philip Empey, director of the Center for Clinical Pharmaceutical Sciences at the University of Pittsburgh and senior author of the paper, emphasized that these results highlight the urgent need for a more personalized approach to prescribing. "If you have a prior experience with a medicine that did not work for you, or had a side effect, we can’t say it’s absolutely because of genetics," Empey explained. "But we are appreciating more and more that people are different, and genetics is one reason that may suggest where there may be differences."
A Brief History of the All of Us Initiative
The All of Us Research Program is the flagship component of the Precision Medicine Initiative, which was announced by President Barack Obama in his 2015 State of the Union address. The vision was to move medicine away from a "one-size-fits-all" model toward treatments tailored to an individual’s genetic makeup, lifestyle, and environment.

- 2015: The Precision Medicine Initiative is announced.
- 2016: The 21st Century Cures Act is signed into law, providing a multi-year funding structure for the program.
- 2018: The All of Us program officially opens for national enrollment.
- 2023: The program begins enrolling children to expand the scope of long-term longitudinal data.
- 2026: The program faces a critical funding cliff as initial legislative appropriations expire.
The success of the program relies on the "longitudinal" nature of the data—tracking participants over years rather than capturing a single snapshot in time. This is essential for understanding how genetics interact with aging, disease progression, and the accumulation of environmental exposures.
Barriers to Clinical Integration
Despite the scientific promise, the path from a published paper to the doctor’s office is fraught with obstacles. Currently, genomic sequencing is not a standard part of routine primary care. For the insights provided by this study to become actionable, several systemic shifts must occur:
- Infrastructure: Many clinical health systems lack the electronic medical record (EMR) capabilities to flag potential genetic contraindications in real-time as a physician writes a prescription.
- Provider Education: Most physicians have not received formal training in interpreting pharmacogenomic data, leading to hesitation in ordering tests or acting on the results.
- Complexity: A patient’s drug response is rarely dictated by a single gene; it is often the result of complex interactions between multiple variants, age, liver function, and diet. Translating these "constellations" of data into simple, actionable clinical guidelines remains a major challenge.
The Looming Funding Crisis
The most immediate threat to the future of pharmacogenomic research is the stabilization of federal funding. The All of Us program has historically relied on two primary funding streams: the 21st Century Cures Act and annual congressional appropriations. With the Cures Act funding set to expire in the 2027 fiscal year, the program faces a precarious future.
Recent budget negotiations have left the program in a state of uncertainty. While the NIH expects to receive $122 million in funding once a budget is finalized, this figure represents an 80% reduction from the program’s 2023 peak. The consequences of this fiscal contraction are already manifesting on the ground.
Joshua Denny, who led the program until October 2026, described the difficult operational decisions necessitated by these cuts. "The engagement activities, the brick and mortar that we had enrolling at academic medical centers and FQHCs and mobile units—these kinds of things were cut back dramatically," Denny stated. Perhaps most critically for participant trust, the program has had to suspend the return of genetic health-related results to participants, a key benefit that incentivized recruitment and engagement.
The impact also extends to the program’s pediatric initiatives. Sara Van Driest, director of Pediatrics for All of Us, noted that while approximately 5,000 children have been enrolled since 2023, the data remains largely inaccessible to researchers due to the resource constraints required to clean, curate, and analyze pediatric-specific genomic datasets.
"In order to really enroll children at scale and build a dataset that’s going to fuel the future of precision health, we’re going to need stable funding in the years ahead," Van Driest urged. "I should say, increased and stable funding in the years ahead."
Implications for Global Public Health
The findings published in Science Translational Medicine represent more than just an academic achievement; they serve as a proof-of-concept for the necessity of inclusive research. If the medical community ignores the genetic diversity of the global population, it risks exacerbating existing health disparities. Conversely, by embracing a more comprehensive understanding of the human genome, clinicians can move toward a future where the efficacy of a medication is no longer a matter of trial-and-error, but a calculated, data-driven decision.
The challenge now lies in whether policymakers will recognize the long-term economic and human benefits of maintaining this research infrastructure. While the immediate cost of genomic research is high, the downstream costs of adverse drug reactions—which account for millions of hospitalizations annually—are significantly higher. As the All of Us program stands at this crossroads, the data it has already collected serves as a powerful testament to the potential of precision medicine, provided the political will exists to sustain it.



